Hooshmand Sheshbaradaran

Hooshmand Sheshbaradaran has had a diverse and extensive work experience in various roles and companies. Hooshmand has held positions such as Chief Operating Officer at MedMelior / BetterLife Pharma Inc since 2018, as well as a Member of the Board of Directors at Bold Therapeutics Inc since 2019. Hooshmand was also the Head of Global Development Strategy, BD & Marketing Advisory Group at Novateur Ventures Inc from 2015 to 2020. In addition, they have served on the Board of Directors for Centigram International Ltd, Intezyne Technologies Inc, and Psioxus Therapeutics. Prior to these roles, they were the President and CEO of Niiki Pharma Inc and held positions at Zeneus Pharma, Roche, and Pharmacia Inc.

Hooshmand Sheshbaradaran earned a Doctor of Medical Science (PhD) in Virology from Karolinska Institutet in the years 1980 to 1985. Prior to that, they obtained a Bachelor of Science (BSc) Honours in Biochemistry and another one in Microbiology and Immunology, both from Queen's University Belfast, although the specific start and end years for these degrees are not provided.